Working languages: English to Chinese
Chinese to English
|  William Wu
Former senior PR Newswire translator
Nanjing, Jiangsu, China Local time: 00:03 CST (GMT+8)
Native in: Chinese | | |
Freelancer and outsourcer,  Verified site user | | Translation, Editing/proofreading, Website localization, Software localization, Subtitling, Training, Desktop publishing | | Specializes in: | | Marketing / Market Research | Advertising / Public Relations | | Tourism & Travel | Business/Commerce (general) | | Medical: Health Care | Law: Patents, Trademarks, Copyright | | Environment & Ecology | Finance (general) | | Transport / Transportation / Shipping | Automotive / Cars & Trucks |
| Also works in: | | Chemistry; Chem Sci/Eng | Journalism | | Accounting | Architecture | | Automation & Robotics | Certificates, Diplomas, Licenses, CVs | | Construction / Civil Engineering | Computers (general) | | Computers: Systems, Networks | Cooking / Culinary | | Textiles / Clothing / Fashion | Insurance | | Engineering (general) | Cinema, Film, TV, Drama | | Law (general) | Investment / Securities | | Internet, e-Commerce | Petroleum Eng/Sci | | Science (general) | Law: Taxation & Customs | | Wine / Oenology / Viticulture | Games / Video Games / Gaming / Casino | | Social Science, Sociology, Ethics, etc. | Medical: Pharmaceuticals | | Human Resources | IT (Information Technology) | | History | General / Conversation / Greetings / Letters | | Mining & Minerals / Gems | Cosmetics, Beauty | | Law: Contract(s) |
More Less | | PRO-level points: 131, Questions answered: 77, Questions asked: 33 | 3 entriesAccess to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
More Less | | MasterCard, Wire transfer | | 4-9 employees | | 2001 | | Chinese yuan (cny), Euro (eur), U. S. dollars (usd) | Sample translations submitted: 3 | English to Chinese: PR Newswire | Source text - English
Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Abbott Innovations Honored for Third Time in Five Years
ABBOTT PARK, Ill., Oct. 22 /PRNewswire-FirstCall/ --
Abbott (NYSE: ABT) has received a 2007 Chicago Innovation Award for its m2000(TM) molecular diagnostic instrument
(www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0021.htm )
and the Abbott RealTime HIV-1 viral load test, the most sensitive test of its kind capable of detecting and precisely measuring all known strains of the human immunodeficiency virus (HIV).
Abbott's RealTime HIV-1 test, approved for use in the United States in May 2007, and run on the m2000 system, is the only viral load test of its kind that can detect and measure all group M, group N and group O strains of HIV-1 as well as non-B subtypes of the virus. The products offer physicians a quick and highly accurate test method to help ensure their patients receive the most effective treatment.
This is the third time in five years Abbott has been selected for a Chicago Innovation Award. In 2005, the company's PathVysion(TM) (http://www.pathvysion.com ) breast cancer test received the honor, and in 2003, HUMIRA(TM)(http://humira.com ), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.
"At Abbott we're in the business of improving lives -- often saving lives. That's an important motivation in fostering innovation," said Miles D. White, chairman and chief executive officer, Abbott. "Patients depend on us for new and better medicines, diagnostics and nutritionals, and that inspires our scientists everyday. The m2000 and HIV-1 viral load test, PathVysion and HUMIRA are just a few examples of the caliber of research being conducted at Abbott to find solutions to unmet medical needs."
Sponsored by Kuczmarski and Associates and the Chicago Sun-Times, the Chicago Innovation Awards are intended to create awareness of the contributions of Chicago-area companies in developing innovative products that change the world. Abbott and other awardees will be recognized at a ceremony and reception tonight at the Goodman Theatre attended by some 400 local business, academic and government leaders.
| Translation - Chinese
雅培的 m2000(TM) 分子诊断仪与实时 HIV-1 检测获“芝加哥创新奖”
五年内雅培第三次获得该创新大奖
美通社-FirstCall 伊利诺伊州 Abbott Park 10月22日电
雅培 (Abbott) (NYSE: ABT) 的 m2000(TM) 分子诊断仪 (www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0021.htm ) 和雅培实时 HIV-1 病毒载量检测已经获得了2007年芝加哥创新奖 (Chicago Innovation Award)。雅培实时 HIV-1 病毒载量检测是同类检测中最敏感的检测，能够检测并准确测量所有已知的人体免疫缺陷病毒 (HIV) 毒株。
雅培的实时 HIV-1 检测于2007年5月获批在美国使用，并运行在 m2000 系统上。该检测是其同类检测中唯一一项能够检测并测量所有 M 组、N 组 和 O 组的 HIV-1 毒株以及非 B 亚型 HIV-1 的病毒载量检测。这些产品为医生提供了一种既快又高度准确的检测方法，从而帮助确保他们的患者能够接受最有效的治疗。
这已经是五年里雅培第三次获得芝加哥创新奖。2005年，该公司的 PathVysion(TM) (http://www.pathvysion.com ) 乳腺癌检测获得了该项殊荣，此外，2003年，HUMIRA(TM) (http://humira.com )——首种用于类风湿性关节炎的人源单克隆抗体药物，获得了该奖项。
雅培董事长兼首席执行官 Miles D. White 表示：“在雅培，我们的工作就是改善生命质量——通常是挽救生命。在培养创新方面，这是一个很重要的动机。患者依靠我们来获得更好的新药物、诊断与营养，而这每天都鼓舞着我们的科学研究人员。在雅培开展的旨在寻找应对医学需求的解决方案的优秀研究有许多，而 m2000 与 HIV-1 病毒载量检测、PathVysion 以及 HUMIRA 只是其中的几个。”
芝加哥创新奖由 Kuczmarski and Associates 和《芝加哥太阳时报》(Chicago Sun-Times) 主办，旨在对芝加哥地区的一些公司所做的贡献予以认可。这些公司开发了一些能够改变世界的创新型药物。今天晚上在 Goodman Theatre 举行的典礼与招待会上将对雅培和其他获奖者进行表彰。约400名当地商界、学术界与政界领导者将出席该次典礼。
| | English to Chinese: forbes | Source text - English
But sex scandals loom so large throughout the West because of a free (and aggressive) press--a phenomenon magnified by technology. In Washington blogger Mike Rogers uses the Web to "out" gay government staffers and members of Congress. Naomi Seligman Steiner, deputy director of the watchdog group Citizens for Responsibility and Ethics in Washington, says the rise of the Internet and 24-hour cable news has empowered the public with an "insatiable appetite" for scandal.
That was the case in Indonesia last year, when a member of parliament resigned after a video clip of him frolicking with a local pop singer surfaced on the Web. The singer reportedly said she took the video with her cellphone, but did not know how the video made its way to the Internet. Her popularity surged; his did not.
In Pictures: A World Of Sex Scandals
| Translation - Chinese
但在西方世界，性丑闻如此频繁地出现在人们的视线是因为自由（乃至激进）的新闻言论——科技的发展进一步放大了这一现象。华盛顿博客写手 Mike Rogers 利用网络将美国政府官员和国会议员中的同性恋者一一曝光。华盛顿监管机构 Citizens for Responsibility and Ethics 副主任 Naomi Seligman Steiner 说，互联网的普及以及全天候有线电视新闻播放使公众对丑闻“乐此不疲”。
去年，印尼一名国会议员因其调戏一名流行歌手的视频在网络上曝光而被迫辞职。据闻这名歌手用她的手机拍下了这段视频，但视频为何会在互联网上流传还不得而知。这名议员为此名声扫地；但这名歌手却因此迅速窜红。
组图：性丑闻世界
| | Chinese to English: Multinational pharmaceutical companies march into Chinese market; Capital bottleneck of for local R&D needs to be removed | Source text - Chinese
跨国药企大举进入 本土研发资金瓶颈待破
随着中国经济与科研的快速发展中国已经成为战略要地，跨国制药企业纷纷来到中国进行药品研发活动。业内普遍认为，随着阿斯利康、礼来、罗氏、拜耳、诺华、葛兰素史克、罗氏等实力雄厚的跨国公司在华建立上下游一体化研发中心，意味着跨国药企在华研发正在向药物开发的核心进发。
日前，罗氏宣布在上海成立罗氏药品开发中国中心。据悉，这是中国乃至亚太地区（不包括日本）第一个全功能临床药品开发中心。罗氏是首个将药品临床开发全过程所需要的全套功能带到中国的跨国药企。据介绍，该开发中心拥有完整的药品开发功能，包括从早期创新的探索设计开始，到高效率的后期临床开发，直至完成产品上市的注册申请。
对于选择中国市场的原因，罗氏全球药品开发部负责人Jean-Jacques Garaud表示有四个方面的考虑，首先是市场因素和影响力，预计到2010年中国医药市场将成为世界上第三大医药市场；其次是完成在中国的药品临床布局；在中国成立开发中心可以更好地了解中国当地的病人和需要，与中国的治疗市场更贴近；第三是中国政府支持制药行业加大研发力度，不断开发新药；第四是中国有丰富的专业人才和良好的技术力量。
罗氏集团董事会主席兼首席执行官胡沫认为，跨国制药公司在中国研发投资的可行性需要综合考虑以下因素：充足的人才储备、健全的监管机制、开放的科研环境。实际上，专家分析指出，更重要的是，可以有效地降低研发成本，分散研发的风险，缩短新药研发周期，加快上市步伐。
业内分析人士表示，我国新药研发的最大瓶颈在于资金不足。其次是非常缺乏医药研发方面的人才，跨国制药企业的进入使这种人才危机加剧。胡沫表示，“这个行业是一个高风险和高投入的行业。”
专家指出，跨国公司在中国建立研发中心在一定程度上能促进中国医药企业的自主创新，也能为中国带来先进的研发管理体系和做法。
| Translation - English
Multinational pharmaceutical companies march into Chinese market; Capital bottleneck of for local R&D needs to be removed
With the fast development of the its national economy and its scientific research sector, China has become a strategic location and for multinational pharmaceutical companies who are come marching intoto the country one after the other to conduct research and development (R&D) in succession. To date, such powerful multinationals as AstraZeneca, Eli Lilly, Bayer, Novartis, GlaxoSmithKline and Roche have set up vertically integrated R&D centers in China. It is generally believed in the industry. The consensus among industry analysts is that this these moves marks the march entry of the multinationals into the core area of drug development.
Most recently, Roche announced the establishment of its Shanghai-based China drug development center. This fully-featured equipped clinical drug development center, featuring complete development capability ranging from early innovative design exploration to effective late clinical development and to registration of the developed product with the authorities, is the first of its kind in China and the Asia-Pacific region except Japan. As a result, Roche became the first multinational pharmaceutical company to bring the full capacity of clinical drug development to China.
Jean-Jacques Garaud, global head of pharmaceutical development for Roche, explained the gave four reasons why the company for selected selecting to place these facilities in the Chinese market China: a. China is expected to become the world's third largest pharmaceutical market by 2010; b. setting up a development center in China will enable Roche to known understand the particular needs of local patients those seeking local medical services better and their needs better and to get closer access to the Chinese therapeutic market; c. the Chinese government of China is making great efforts to help thrown a lot of weight behind helping the pharmaceutical industry sector continue to develop new drugs by intensifying focusing on research and development; and d. China has plenty a plethora of professionals and boasts good technical strength.
Franz B. Humer, chairman and CEO of Roche, indicated that, in studying the feasibility of making R&D investments in China, multinational pharmaceutical companies need to consider the following factors: sufficient availability of talent reserve, a sound regulatory mechanism and an open research environment. More importantly, said industry analysts, making such investments in China can not only bring down R&D costs but also disperse R&D risks, shorten the R&D cycle of for new drugs and accelerate time to market.
"This is an industry with high risks and requiring high steep investments," said Humer.
The biggest bottleneck of in China's research and development of new drugs lies in the inadequate funding, which is followed by the lack of professionals specializing in drug R&D, and t. The arrival of multinational pharmaceutical companies is worsening aggravating the already tight market for talent situation, according to the analysts.
The analysts expect the establishment of China-based R&D centers by multinationals to boost independent innovation of among China's pharmaceutical companies to some extent, as well as to bring about the establishment of advanced R&D management systems and practices for in China.
|
More Less | | SDL Certified | | Years of translation experience: 5. Registered at ProZ.com: Feb 2008. | | N/A | English to Chinese (Science and Technology Translators' Association of the Chinese Academy)
English to Chinese (TEM8)
Chinese to English (TEM8)
| | ATA, AAIT | | E&C Translation Team, E&C Translation Team | | Across, Adobe Acrobat, Adobe Illustrator, Adobe Photoshop, AutoCAD, Dreamweaver, FrameMaker, Frontpage, Indesign, Microsoft Excel, Microsoft Word, Powerpoint, SDL TRADOS, SDLX, Wordfast | | http://www.EnglishandChinese.com.cn/index.html | | William Wu endorses ProZ.com's Professional Guidelines (v1.0). | | About me William Wu
1 Gaohu Road, Jiangning District, Nanjing, China 211100
Tel: +86 25 52783041 Fax: +86 25 52783042 Cell: +86 13851908456
E-Mail: wulianpo@yahoo.com.cn MSN: lianpo_wu@hotmail.com Skype: wulianpo QQ:52783041
Former PR
Newswire Translator and Project Manager
Team Leader of E&C Translation
Strong business news translation background;
Profound knowledge in financial areas;
Five years translation experience (including one year as a freelancer);
Translated well over two million words/characters (roughly);
Half-year US training experience, deep understanding of English-speaking country cultures.
Expertise
Business News: Three years experiences with PR Newswire and translation of over one million words/characters in business areas.
Banking/Finance: Translation of approx. 100,000 words of banking documents for China Construction Bank Johannesburg Branc.
Health Care: Translation of approx. 20,000 words of health care documents for a Canadian client.
Website Localization: Engaged in the localization of the websites of The Federation of International Trade Associations (FITA) and Ingersoll Rand and independently finish the website localization for PokerListings and Pool Sharks (both are online gaming websites).
Other Working Fields
| Oil & Energy | Air Compressor | Wine | Medicine (general) |
| Software Manuel | Fashion | Luxuries (Watch and Sun Glasses |
|Grinding Machine | Auto Industry | Gambling | Online Poker |
| Online Pool & Snooker |
Documents Dealt With
Press Releases:
PR Newswire's daily news releases
Financial:
| Annual/quarterly reports | Audit report | Business plan | Feasibility studies | Financial statements | General business correspondences | Investment funds prospectus | IPO prospectus | Product documentation |
Legal:
| Articles of Association | Loan Agreements | Guaranties | Joint Venture Agreements | Lease Contracts | Management Agreements | Memorandum of Understanding | Merger and Acquisition Agreements | Minutes of Board of Directors | Non-Disclosure Agreements | Pledge Agreements | Proxy Agreements | Shareholder Agreements | Trust | Warrant
Health Care
Website Localization
Localization Projects Dealt with:
1. FITA (http://fita.org)
2. MATRADE (http://www.matrade.gov.my/)
3. www.pokerlistings.hk (En>Mandarin);
4. www.clubasiacasino.com/English/
(Cantonese Version: http://www.clubasiacasino.com/Traditional/Default.aspx ; Mandarin Version:http://www.clubasiacasino.com/Simplified/Default.aspx );
5. http://www.poolsharks.com.cn/ (En> Mandarin); and
6.http://www.ultimatebet.com/ (En> Mandarin).
Academic Background
B.S., E-Business, South-East University, China, 1999
M.A., English Literature, Nanjing University of Aeronautics and Astronautics, China, 2002
Computer Systems
Hardware:
MacBook
CPU: Core 2 Duo 2.10GHz;
Memory: 1GB DDR
Software:
Microsoft Office Suite 2003;
SDL Trados 7;
SDL MultiTerm 7;
Adobe Illustrator;
Adobe InDesign;
Adobe Acrobat;
Adobe Shotoshop;
MacroMedia DreamWeaver.
| This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
This user has reported completing projects in the following job categories, language pairs, and fields.
| Project History Summary |
|---|
| Total projects | 1 | | With client feedback | 0 | | Corroborated | 0 | | | 0 positive (0 entries) |  positive | 0 |  neutral | 0 |  negative | 0 |
| Job type | | Translation | 1 | | | Language pairs | | English to Chinese | 1 | | | Specialty fields | | | Other fields | | Medical (general) | 1 |
|
|
|
Keywords: Business Translation
Annual reports
Financial statements
Projections
Pension plans
Fact sheets Release notes
Patents
Software documentation
Procedures
Functional specifications
Design specifications
Technical reports
Manuals and user guides
Car servicing manuals
Confidential government documents
Business-to-business and business-to-consumer marketing and advertising materials
Business-to-business and business-to-consumer Web sites
Focus group transcripts
translation of press releases, press kits, public relations, marketing and advertising literature, technical and instruction manuals, magazine and newspaper articles, market reports and surveys, corporate annual reports, stock prospectuses, related presentation materials, business translation
Profile last updated
Aug 14, 2010 |
The translation workplace 
Dynamic content (javascript) disabled in this profile. FAQ 
Expertise